PhenoAgeAccel与糖尿病和前驱糖尿病患者的全因死亡率和心血管死亡率相关：一项队列研究

IF 6.1 3区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes research and clinical practice Pub Date : 2025-07-12 DOI:10.1016/j.diabres.2025.112375

Junyu Xi , Zeyu Zhang , Baoluo Hou , Yuqi Wu , Yifei Zhang , Weijing Liu

{"title":"PhenoAgeAccel与糖尿病和前驱糖尿病患者的全因死亡率和心血管死亡率相关：一项队列研究","authors":"Junyu Xi , Zeyu Zhang , Baoluo Hou , Yuqi Wu , Yifei Zhang , Weijing Liu","doi":"10.1016/j.diabres.2025.112375","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><div>Phenotypic Age Acceleration (PhenoAgeAccel) is a measure of biological aging, with higher scores indicating faster aging. Few studies have explored its association with mortality in patients with diabetes or prediabetes. This study aimed to investigate the predictive value of PhenoAgeAccel for all-cause and cardiovascular mortality in these patients.</div></div><div><h3>Methods</h3><div>NHANES data (1999–2018) from 15,939 participants were analyzed. Phenotypic age was calculated from biomarkers such as albumin, creatinine, and glucose, and PhenoAgeAccel was defined as the residual from regressing phenotypic age on actual age. Mortality associations were assessed via Kaplan-Meier, Cox models, restricted cubic spline (RCS), and subgroup analyses.</div></div><div><h3>Results</h3><div>Per 1-year increase in PhenoAgeAccel was associated with a 5.1 % higher risk of all-cause mortality (HR = 1.051, 95 % CI: 1.046–1.057) and a 5.4 % increased risk of cardiovascular mortality (HR = 1.054, 95 % CI: 1.044–1.065) in patients with diabetes or prediabetes. Highest-quartile (Q4) patients had 191.9 % higher all-cause mortality and 192.6 % higher cardiovascular mortality versus Q1 (both p < 0.001). RCS analysis revealed linear positive associations of PhenoAgeAccel with both all-cause and cardiovascular mortality (both P-nonlinear > 0.05).</div></div><div><h3>Conclusion</h3><div>Higher PhenoAgeAccel is associated with increased all-cause and cardiovascular mortality in patients with diabetes and prediabetes.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"226 ","pages":"Article 112375"},"PeriodicalIF":6.1000,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PhenoAgeAccel is associated with all-cause and cardiovascular mortality in patients with diabetes and prediabetes: A cohort study\",\"authors\":\"Junyu Xi , Zeyu Zhang , Baoluo Hou , Yuqi Wu , Yifei Zhang , Weijing Liu\",\"doi\":\"10.1016/j.diabres.2025.112375\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Aims</h3><div>Phenotypic Age Acceleration (PhenoAgeAccel) is a measure of biological aging, with higher scores indicating faster aging. Few studies have explored its association with mortality in patients with diabetes or prediabetes. This study aimed to investigate the predictive value of PhenoAgeAccel for all-cause and cardiovascular mortality in these patients.</div></div><div><h3>Methods</h3><div>NHANES data (1999–2018) from 15,939 participants were analyzed. Phenotypic age was calculated from biomarkers such as albumin, creatinine, and glucose, and PhenoAgeAccel was defined as the residual from regressing phenotypic age on actual age. Mortality associations were assessed via Kaplan-Meier, Cox models, restricted cubic spline (RCS), and subgroup analyses.</div></div><div><h3>Results</h3><div>Per 1-year increase in PhenoAgeAccel was associated with a 5.1 % higher risk of all-cause mortality (HR = 1.051, 95 % CI: 1.046–1.057) and a 5.4 % increased risk of cardiovascular mortality (HR = 1.054, 95 % CI: 1.044–1.065) in patients with diabetes or prediabetes. Highest-quartile (Q4) patients had 191.9 % higher all-cause mortality and 192.6 % higher cardiovascular mortality versus Q1 (both p < 0.001). RCS analysis revealed linear positive associations of PhenoAgeAccel with both all-cause and cardiovascular mortality (both P-nonlinear > 0.05).</div></div><div><h3>Conclusion</h3><div>Higher PhenoAgeAccel is associated with increased all-cause and cardiovascular mortality in patients with diabetes and prediabetes.</div></div>\",\"PeriodicalId\":11249,\"journal\":{\"name\":\"Diabetes research and clinical practice\",\"volume\":\"226 \",\"pages\":\"Article 112375\"},\"PeriodicalIF\":6.1000,\"publicationDate\":\"2025-07-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes research and clinical practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0168822725003894\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes research and clinical practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168822725003894","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

目的：表型年龄加速（PhenoAgeAccel）是一种生物衰老的测量方法，得分越高表明衰老越快。很少有研究探讨其与糖尿病或前驱糖尿病患者死亡率的关系。本研究旨在探讨PhenoAgeAccel对这些患者全因死亡率和心血管死亡率的预测价值。方法：分析来自15,939名参与者的NHANES数据（1999-2018）。表型年龄是根据白蛋白、肌酐和葡萄糖等生物标志物计算出来的，而PhenoAgeAccel被定义为表型年龄对实际年龄的回归残差。通过Kaplan-Meier、Cox模型、限制性三次样条（RCS）和亚组分析评估死亡率相关性。结果：在糖尿病或糖尿病前期患者中，每增加1年，PhenoAgeAccel的全因死亡率风险增加5.1 % (HR = 1.051, 95 % CI: 1.046-1.057)，心血管死亡率风险增加5.4 % （HR = 1.054, 95 % CI: 1.044-1.065）。与Q1相比，最高四分位数（Q4）患者的全因死亡率高191.9 %，心血管死亡率高192.6 %（两个终点的p均为  0.05）。结论：较高的PhenoAgeAccel与糖尿病和前驱糖尿病患者的全因死亡率和心血管死亡率增加有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

PhenoAgeAccel is associated with all-cause and cardiovascular mortality in patients with diabetes and prediabetes: A cohort study

Aims

Phenotypic Age Acceleration (PhenoAgeAccel) is a measure of biological aging, with higher scores indicating faster aging. Few studies have explored its association with mortality in patients with diabetes or prediabetes. This study aimed to investigate the predictive value of PhenoAgeAccel for all-cause and cardiovascular mortality in these patients.

Methods

NHANES data (1999–2018) from 15,939 participants were analyzed. Phenotypic age was calculated from biomarkers such as albumin, creatinine, and glucose, and PhenoAgeAccel was defined as the residual from regressing phenotypic age on actual age. Mortality associations were assessed via Kaplan-Meier, Cox models, restricted cubic spline (RCS), and subgroup analyses.

Results

Per 1-year increase in PhenoAgeAccel was associated with a 5.1 % higher risk of all-cause mortality (HR = 1.051, 95 % CI: 1.046–1.057) and a 5.4 % increased risk of cardiovascular mortality (HR = 1.054, 95 % CI: 1.044–1.065) in patients with diabetes or prediabetes. Highest-quartile (Q4) patients had 191.9 % higher all-cause mortality and 192.6 % higher cardiovascular mortality versus Q1 (both p < 0.001). RCS analysis revealed linear positive associations of PhenoAgeAccel with both all-cause and cardiovascular mortality (both P-nonlinear > 0.05).

Conclusion

Higher PhenoAgeAccel is associated with increased all-cause and cardiovascular mortality in patients with diabetes and prediabetes.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Diabetes research and clinical practice 医学-内分泌学与代谢

CiteScore

10.30

自引率

3.90%

发文量

862

审稿时长

32 days

期刊介绍： Diabetes Research and Clinical Practice is an international journal for health-care providers and clinically oriented researchers that publishes high-quality original research articles and expert reviews in diabetes and related areas. The role of the journal is to provide a venue for dissemination of knowledge and discussion of topics related to diabetes clinical research and patient care. Topics of focus include translational science, genetics, immunology, nutrition, psychosocial research, epidemiology, prevention, socio-economic research, complications, new treatments, technologies and therapy.